Clinical Trials Arena June 13, 2025
The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in participants.
Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability of the technology for sensitive tasks persist.
The limitations of AI to enhance trial participant engagement, and how it may overcome these, were outlined by Blanka Hezelova, associate director at GSK on 11 June. Hezelova spoke on the impact of AI during a keynote address on the second day of the 12th Annual Arena International Outsourcing in Clinical Trials UK & IR conference held in London.
Hezelova said the clinical trial industry is in a “transition period”, such that much of...
Today's Sponsors
Today's Sponsor